Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
CPRIT-backed startup March Biosciences advances CD5 CAR T program after accelerator and grant funding
Summary
March Biosciences, a CPRIT-supported company that emerged from the Texas Medical Center accelerator, reported early clinical progress in a CD5-directed CAR T trial and said CPRIT funding helped catalyze Series A support.
March Biosciences, a Houston-based cell-therapy company that received seed support through CPRIT-funded accelerator programs and a CPRIT grant, reported clinical progress on its CD5-directed autologous CAR T program (MB105) during the Aug. 20 CPRIT oversight meeting.
Founder and CEO Sarah Hine told the oversight committee that MB105, being developed initially for T-cell lymphomas, produced promising complete responses in early academic-phase…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
